NCT04182594 is a Phase 2 clinical trial of Degarelix in Hormone Sensitive Prostate Cancer, sponsored by Rabin Medical Center.

Who is sponsoring NCT04182594?

NCT04182594 is sponsored by Rabin Medical Center.

What drugs are being tested in NCT04182594?

Interventions in NCT04182594: Degarelix, GnRH agonist.

What condition does NCT04182594 study?

NCT04182594 studies Hormone Sensitive Prostate Cancer, Prostate Cancer, Cardiac Event.

Is NCT04182594 still recruiting?

NCT04182594 is currently status unknown. Last updated 2 December 2019.

Last reviewed 2019-12-02 · How we verify

NCT04182594

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cardiovascular Events in GnRH Agonist vs. Antagonist

Status unknown Phase 2 Last updated 2 December 2019

What this trial tests

Phase 2 trial testing Degarelix in Hormone Sensitive Prostate Cancer in 80 participants. Status unknown.

Timeline

17 January 2020

Primary endpoint
17 January 2023

17 January 2023

Quick facts

Lead sponsor	Rabin Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	80
Start date	17 January 2020
Primary completion	17 January 2023
Estimated completion	17 January 2023
Sites	1 location across Israel

Drugs / interventions tested

Degarelix (degarelix) — full drug profile →
GnRH agonist — full drug profile →

Conditions studied

Hormone Sensitive Prostate Cancer — all drugs for Hormone Sensitive Prostate Cancer →
Prostate Cancer — all drugs for Prostate Cancer →
Cardiac Event — all drugs for Cardiac Event →

Sponsor

Rabin Medical Center

Who can join

Adults 18 to 90, male only, with Hormone Sensitive Prostate Cancer or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test if the use of Degarelix for 1 year associated with a lower rate of cardiovascular toxicity compared to Gonadotropin-releasing hormone (GnRH) agonists in patients with advanced prostate cancer and cardiovascular risk factors, receiving combination therapy of Androgen deprivation therapy (ADT) and second line hormonal or chemotherapy?

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiovascular Toxicities of Androgen Deprivation Therapy.
Challa AA, Calaway AC, Cullen J, Garcia J, et al · · 2021 · cited 37× · PMID 33866442 · DOI 10.1007/s11864-021-00846-z
Degarelix for treating advanced hormone-sensitive prostate cancer.
Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, et al · · 2021 · cited 14× · PMID 34350976 · DOI 10.1002/14651858.cd012548.pub2

Verify or expand the search:

Other trials of Degarelix

Trials testing the same drug.

NCT07335796 — A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer · Phase 2 · recruiting
NCT05873192 — Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer · Phase 2 · recruiting
NCT06378866 — Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati · Phase 2 · recruiting
NCT06264882 — Cardiometabolic Consequences of the Loss of Ovarian Function · Phase 4 · recruiting
NCT05501704 — ETHAN - ET for Male BC · Phase 2 · recruiting

Other recruiting trials for Hormone Sensitive Prostate Cancer

Currently open trials in the same condition.

NCT07028853 — This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W · Phase 3 · recruiting
NCT06463457 — Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) · Phase 2 · active not recruiting
NCT06392295 — PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer · Phase 2 · recruiting
NCT06479187 — PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer · Phase 4 · active not recruiting
NCT05983783 — Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC · Phase 3 · recruiting

Other Rabin Medical Center trials

Trials by the same sponsor.

NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04182594 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
Last refreshed: 2 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04182594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing